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ABSTRACT 
The workshop on Three Rs Approaches in the Production and Quality Control of Fish Vaccines aimed    
a) to identify animal tests currently stipulated for the production and quality control of fish vaccines and to 
highlight animal welfare concerns associated with these tests; b) to identify viable options to replace, 
reduce, and refine animal use for fish vaccine testing; and c) to discuss the way forward and set out how 
the Three Rs may be implemented without jeopardizing the quality of the vaccines. The workshop 
participants -- experts from academia, regulatory authorities, a scientific animal welfare organization, and 
the fish vaccine industry -- agreed that efforts should be undertaken to replace the vaccination challenge 
batch potency testing with tests based on antigen quantification or antibody response tests. Regulatory 
requirements of questionable scientific value and relevance for the quality of fish vaccines, such as the 
re-testing of batches produced outside Europe, or the double-dose batch safety test, should be re-
considered. As an immediate measure the design of the current animal tests should be evaluated and 
modified in the light of refinement and reduction, for example, the number of unprotected control fish in 
vaccination-challenge tests should be reduced to the minimum. 
1. Introduction 
The European Centre for the Validation of Alternative Methods (ECVAM) organized a workshop on Three 
Rs Approaches in the Production and Quality Control of Fish Vaccines. The workshop took place on 
29e31 January 2008 in Ispra, Italy. The main objectives of the workshop were a) to identify animal tests 
currently stipulated for the production and quality control of fish vaccines and to highlight animal welfare 
concerns associated with these tests; b) to identify viable options to reduce, refine and replace animal 
use for fish vaccine testing; and c) to discuss the way forward and set out how replacement, reduction 
and refinement (Three Rs, [1]) may be implemented more actively. 
Driven by remarkable successes in disease prevention and control, there is a significant increase in 
vaccination against bacterial and viral infections in European aquaculture, and a corresponding increase 
in vaccine supply to European markets. According to current regulatory guidelines, in vivo methods are 
still dominating the evaluation of current and new vaccines for fish. Consequently, there is an increase in 
the number of fish used during the development, licensing and quality control of fish vaccines. In Norway, 
which is the leading producer of farmed salmonids and the major user of fish vaccines in Europe, this has 
led to fish outnumbering all other animal species used for biomedical research [2]. Furthermore, 
regulatory requirements stipulate immunization challenge tests to demonstrate the efficacy of fish 
vaccines, and such tests are also recommended to confirm potency before batch release. Because 
unprotected fish will develop disease and illness during such tests, these procedures are of greater 
concern with respect to animal welfare than those which do not involve experimental challenge (e.g. 
serological tests). The potential for adverse reactions, and for test procedures to cause pain, suffering 
and distress, applies to fish in the same way as any other species.  
In this context, experts from academia, regulatory authorities, a scientific animal welfare organization and 
the fish vaccine industry participated in the workshop, contributing unique scientific data, their personal 
experience, scientific skills and judgment. At the time of writing, several essential aspects relevant to 
animal welfare in fish are scarcely researched or may be subject to divergent interpretation (e.g. the 
nature of pain sensation and cognition in fish). However, the participants agreed on two overall goals. The 
first was to focus on how replacement, reduction and refinement of animal tests [1] could be further 
implemented particularly regarding procedures perceived as the “most severe”. The second was to 
explore how animal tests of questionable relevance could be avoided in the production and quality control 
of fish vaccines. 
Before presenting the outcome of the workshop, background information is provided on relevant topics 
such as the immune system of fish, the capacity of fish to experience pain, suffering and distress, and 
current fish vaccine testing requirements. Each of these has implications for the importance of and/or 
ability to implement the Three Rs concept in the quality control of fish vaccines. 
1.1. The immune system of fish 
The most prominent macroscopic differences between mammalian and teleost immune systems are the 
location and distribution of relevant cells, tissues and organs, especially the sites for hematopoiesis. The 
obvious differences are that fish lack bone marrow, lymph nodes and Peyer’s patches, and instead the 
kidney is a major lymphoid organ in the teleosts in addition to the thymus, spleen and mucosa-associated 
lymphoid tissues [3,4]. Primary lymphoid organs seem to be the thymus (T-cells) and kidney (B-cells) [5]. 
The foremost part of the kidney shows morphological similarities with the bone marrow in higher 
vertebrates [6] but it also serves as a secondary lymphoid organ, and together with the spleen can be 
viewed as a lymph node analog important in the induction and elaboration of immune responses [7]. It 
appears that four out of the five classical inflammatory signs may be present in fish; swelling (tumor), 
redness (rubor), pain (dolor), and loss of function (functio laesa) but being poikilothermic animals, heat 
(calor) is not obviously associated with inflammation in fish. Mast-like cells (eosinophilic granule cells) are 
present but lack histamine in their granules [8], however, they degranulate following intraperitoneal 
injection with various phlogistic agents including mast cell degranulation agent 48/80 [9] suggesting that 
they induce vascular changes. The humoral components of the innate immune system of fish are 
numerous, with different functions and include growth inhibitors, various lytic enzymes, components of the 
complement pathway, agglutinins and precipitins, natural antibodies, cytokines, chemokines and 
antibacterial peptides. An overview of the innate immune system of fish can be found in [4,10]. The 
current status of the adaptive immune system in fish has been recently reviewed [3]. The effector cells of 
this system are two types of lymphocytes, B-cells that play the effector role in the humoral immune 
response, whereas T-cells are intimately involved in cell-mediated immune responses. Alongside with the 
lymphocytes is the presence of antigen presenting MHC class I and class II molecules however in all 
teleosts studied so far including salmonids the MHC class I and II regions are unlinked [11]. 
The availability of well-characterized B cell-specific anti-IgM monoclonal antibodies (mabs) for many fish 
species has facilitated more researchon B-cells compared to T-cells. Compared to mammals, fish B cell 
responses differs in many aspects. They do not show an Ig class switch, and the only classes detected so 
far is a tetrameric homolog of IgM as predominant serum immunoglobulin and two other types, IgD and 
IgT [12-14]. In contrast to mammalians, B-cells from teleost fish show potent in vitro and in vivo 
phagocytic activities [15]. Bonyfish respond however poorly to immunization compared to mammals as 
they produce antibodies with lower affinity for the antigen as affinity maturation has not been detected in 
fish [16]. 
Detailed functional studies of piscine T-cells in major aquaculture species are currently hindered due to 
lack of antibodies for detection, but their presence can be concluded from functional studies and 
expression of TCR, CD8 and CD4 genes [3]. Studies on cell-mediated cytotoxicity (CMC) activity in fish 
are also hindered due to highly polymorphic MHC molecules [17] although experimental studies have 
documented MHC-I restricted killing of virus infected target cells [18] and similar findings were reported 
earlier in rainbow trout [19]. To what extent the T helper cell subdivision exists in fish is not known but 
some of the cytokines reflecting both Th1 and Th2 responses have been found in salmonids, zebrafish, 
and pufferfish. 
The second key feature of the adaptive immune response is memory and albeit indications of the 
existence of an immunological memory in fish [20], however, it is not definitively proven.  
In conclusion, the marked differences between the mammalian and piscine immune systems and the 
relative lack of specific reagents may serve to explain why fish vaccine testing still mainly relies on in vivo 
methods, and why the development of alternatives based on serology or antigen quantification test is 
slow. 
1.2. Pain, illness and suffering in fish 
If it is accepted that fish have an awareness of pain, it is important to understand how experimental 
procedures may affect them, so that any suffering can be prevented or minimized [21]. This section 
defines pain, for the purposes of this report, and discusses the evidence for pain perception and suffering 
in fish as it is believed to occur during vaccine research and quality control. Pain can be defined as a 
negative sensory and psychological experience. This splits pain into two components, where there is      
(i) tissue damage giving rise to the sensation of pain and (ii) a negative subjective experience, or suffering 
[22]. Judgments about the capacity of non-human animals to experience pain must be made for each 
species using behavioral, physiological and neurological indicators as a basis. For example, some pain 
research involves recording behavioral and physiological responses to a potentially painful event. If 
normal behavior is suspended and negative or abnormal changes in behavior and physiology occur, then 
it can be inferred that the animal is experiencing a negative affective state alongside the sensory 
component. 
There are a number of other techniques that can be used to deduce whether animals perceive pain. 
Examples are investigating whether the species has the neural machinery (nociceptors) to detect noxious 
stimuli that give rise to the pain sensation, whether analgesics reduce behavioral and physiological 
responses to a potentially painful event, and whether animals can learn to avoid damaging stimuli. 
1.2.1. Sentience, consciousness and cognition of pain 
A number of studies have been conducted using the above techniques to assess the potential for 
nociception and pain in fish. It has been shown that fish do have nociceptors that detect painful stimuli 
[23], with physiological properties that are very similar to those found in mammals [24-28]. In several fish 
species activity patterns differ when the animals are subjected to non-noxious stimuli as opposed to 
painful stimuli [21,29,30]. The use of morphine in trout given a potentially painful stimulus decreased 
anomalous behaviors and prevented the suspension of normal behavior [31]. Fish are capable of learning 
to avoid noxious stimuli and this learning does not occur when morphine is administered, suggesting that 
pain is reduced [32]. Finally, noxiously stimulated trout do not show an appropriate response to a fear test 
and this suggests that pain dominates their attention and is therefore an important and unpleasant state 
to the fish [33,34]. 
While there is evidence for nociception in fish, an animal has to be sentient or conscious in order to 
experience pain. Sentience is the ability to perceive external stimuli and research has shown that fish can 
sense potentially painful stimuli and that their behavior is negatively affected by such stimuli, therefore, it 
could be argued they are aware of/can experience pain. “Higher order” forms of consciousness include 
self-awareness, meta-cognition (having thoughts about thoughts and creating internal representations) 
and finally episodic memory where animals can think about the past and future. Evidence for these higher 
order forms have been demonstrated in birds, rats, dolphins and primates [35-39] but have never been 
explored in fish and so it cannot be stated for certain that they do or do not exist. 
Therefore, the participants in the workshop do not propose that fish have a similar experience of pain to 
humans, but conclude that fish do experience noxious stimuli in a way that has a detrimental effect on 
their behavior, physiology and well-being. It is therefore important that fish are treated in a humane 
manner, including during experimentation. In the case of vaccine research and quality control, this 
especially means minimizing and alleviating any pain caused by procedures that might cause tissue 
damage or by illness that may develop. 
Inferring from human experience, one can argue that most generalized infections are not painful per se. 
Suffering is mainly associated with a general feeling of weakness and poor wellbeing, abnormality in 
physiological functions, negative feelings and anxiety, including the fear of permanent disability or death. 
Thus it appears that suffering in many illnesses is closely associated with the cognitive and mental 
capacities of the sufferer. For the purpose of this report, however, and irrespective of potentially different 
views upon the mental capabilities of fish, it was agreed that inflicting a generalized infection upon 
experimental fish should be regarded as an invasive procedure with the potential to cause suffering. 
Experimental infection may cause weakness, poor wellbeing, clinical illness, tissue damage and 
eventually death. It is therefore important to be able to recognize signs of illness in fish so that humane 
endpoints can be implemented if possible (see 4.4 Welfare assessment). 
1.3. Animal tests stipulated for the production and quality control of fish vaccines 
The regulatory authorities in Europe and North America stipulate animal tests to achieve approval for 
marketing a vaccine and for batch (serial) release of the authorized vaccine. 
A detailed description of the regulatory framework, the various requirements and animal tests are given in 
Appendix A. 
The various tests are briefly summarized and the minimum numbers of animals required are listed in 
Table 1. 
1.3.1. Efficacy testing (prior to product marketing authorization) 
Fish of the target species are vaccinated in the conditions to be recommended for use. They are 
challenged together with the unvaccinated control fish via a specific route and at a fixed interval after 
vaccination. The fish are observed until at least a given percentage of specific mortality is reached in the 
control group. The relative percent survival (RPS) values are calculated and have to meet the specified 
regulatory requirements. 
1.3.2. Safety testing (prior to product marketing authorization)  
The safety of fish vaccines for all recommended uses has to be demonstrated under laboratory and field 
conditions. Fish are vaccinated and, for a given period, observed for local and systemic reactions. 
1.3.3. Batch (serial) potency testing 
Batch/serial potency can be either by a vaccination-challenge test (as described above) or an antibody 
induction test, for which fish are vaccinated and the level of antibodies induced is measured with 
immunochemical methods. Under certain conditions, in vitro methods (e.g. antigen quantification) can be 
used for serial potency testing in the US. 
1.3.4. Batch (serial) safety testing 
According to the European Pharmacopoeia (Ph.Eur.) monographs and European guidelines, the batch 
safety test is carried out with a double dose of the vaccine administered to fish by the recommended 
route and observed for a given period. No fish should show notable signs of disease or die from causes 
attributable to the vaccine. As stated in the Ph.Eur. general monograph on veterinary vaccines, the 
routine application of the batch safety test can be waived for established vaccines in agreement with the 
competent authority provided that consistency of production has been demonstrated for at least 10 
consecutive batches.  
Batch (serial release) safety testing of fish vaccines in the US may be conducted by observation of fish 
after vaccination during vaccination-challenge or vaccination-serology studies. Separate batch safety 
studies in fish are required when potency is demonstrated by in vitro methods or in a non-target host (i.e. 
in a species other than that for which it is recommended). 
2. Potential for replacement 
The highest number of experimental fish is currently being used during the quality control of fish vaccines 
prior to batch release. Replacing in vivo with in vitro methods for quality control of commercial batches of 
vaccines therefore has the potential to significantly reduce the numbers of fish used. 
Following the consistency approach ([40], see also below), the focus of development and licensing, 
including the documentation of safety, may be shifted toward a more comprehensive documentation of  
both, acute and chronic systemic and local reactions. The demonstration of consistency with regard to 
product safety and efficacy, along with prioritized development and validation of alternative potency test 
methods, would allow for the total replacement of animal testing for batch release. If an alternative 
potency test method can be validated before full licensing, there would even be an opportunity for the 
elimination of animal testing in the demonstration of product stability. 
Table 1. Minimum numbers of animals stipulated for the tests required in Europe and North America. 
 Ph.Eur. EU guidelines Canada USA 
Prior to product approval 
for marketing 
    
     
Efficacy 200 Not given 100 fish per challenge organism Usually at least 3 
replicates of 50, 150 
total 
     
Safety 50 Not given 0 (carried out in combination with, 
i.e. pre-challenge part of the  
efficacy)        
0 (carried out in 
combination with 
efficacy) 
Laboratory   
Field 180 or a sufficient number 
of fish distributed in not 
fewer than 2 sets of 
premise 
 no minimum, require safety testing 
of multiple serials at multiple 
geographical locations)a 
1000 
     
Batch/serial testing     
     
Potency 60 Not given 50 fish per challenge organism. In 
vitro potency acceptable if properly 
validated 
In vitro potency 
allowed for batch 
release; challenge or 
serology allowed but 
not required 
Challenge   
Serotology 35  
     
Safety 10 30 or 50 0 (carried out in combination with 
efficacy, i.e, pre-challenge part 
of the efficacy) 
25 
 
2.1. Batch potency testing alternatives based on antigen quantification 
New concepts of quality control can offer alternatives to current vaccination-challenge models. 
The “consistency approach” is based on the principle that the extent of vaccine batch release testing 
should reflect the level of consistency achieved during the production process. It implies the use of a set 
of in vitro measurable parameters (e.g. antigen content and integrity) to constitute a product profile that 
can replace or reduce current release tests. This product profile ensures that each batch is in diverse 
aspects similar to a manufacturer-specific vaccine of well-documented efficacy and safety. Monitoring of 
physiochemical parameters (e.g.pH value, viscosity, amount of inactivating and/or preservative agents) 
will serve to verify consistency of the production process [40]. Gains need to be made to consider batch 
potency by antigen quantification on the key attributes for an acceptable test. There may be an improved 
validation potential, increased reproducibility, differentiation of potent from sub-potent batches, and utility 
to employ the test throughout the shelf-life of the product in the same test system over models involving 
animals. 
A good alternative to a vaccination-challenge test would be to establish methods (e.g. ELISA) for relative 
potency testing by antigen quantification. Such assays should be developed to measure an antigen or 
antigens that are immunologically functional and can be quantified in the final product: 
2.1.1. Technical considerations 
a. The assay could be used both for in-process control and formulation, and also as a potency test 
throughout the shelf-life of the product. Such an assay requires the use of a reference vaccine 
which has been proven to be efficacious in the target animals. The ELISA would be standardized 
to utilize specific antibodies to capture the antigen and quantify the concentration [41]. The 
estimation of batch potency should be based on a “relative potency approach” and has to be in line 
with the requirements outlined in Ph.Eur., Chapter 5.3. “Statistical analysis of results of biological 
assays and tests” [42]. 
b.  The potential for modulation of other antigens in a multivalent formulation might not be captured in 
every type of antigen quantification assay, but can be controlled with additional antigen-based 
tests and specifications on the concentrations of all other antigens in a defined product. Tighter 
specifications for quantification of bacteria or virus particles in vaccines by total particle counts 
(cells or antigenic units) for example will make this more feasible. 
c. The antigen quantification test should be validated according to VICH Guideline 2 [43]. During 
validation it should be demonstrated that the chosen potency test is capable to distinguish 
between standard and sub-potent batches on the basis of antigen content. 
2.1.2. Physico-chemical considerations 
d.  Antigen recovery experiments will show, whether elution is required to quantify the antigen in 
adjuvanted products. e. In addition, the batch control testing would also require an assay to 
estimate the consistency of the final product formulation. Through the validation studies, potential 
effects of antigen-adjuvant formulation such as modulation of the immune response, vaccine 
deposition and slow release, or antigen presentation should be addressed. 
f.  The inactivating and/or preservative agents used in manufacture must be considered during 
validation of an ELISA assay for antigen quantification. The agents may be present in the final 
formulation of the vaccine and the effect and antigen retention capacity of those agents may 
change over time. 
2.1.3. Immunochemical considerations 
g.  The ELISA assay should employ a reference batch of Good Manufacturing Practice vaccine 
produced to the antigen specification as described in the dossier for licensing. Samples of the 
reference vaccine must be kept without degradation and a defined period for use of the reference 
vaccine should be determined. Its stability should be monitored in regular intervals and appropriate 
warning and action limits should be set. A replacing procedure should be established. The 
reference vaccine would be made from an antigen where the dose and function were determined. 
An immunogenicity study of the reference vaccine should be established by validation of potency 
in an in vivo vaccination-challenge model as required in Directive 2001/82 as amended [44]. 
h.  While the quantification of protective antigens is optimal, any antigen that is capable of creating an 
immunological response may be relevant. During development phases, several methods could be 
employed to define a protective or immunorelevant reference antigen for use in ELISA tests. The 
antigen selection could be optimized by harvesting immunoglobulin from convalescent or 
immunized target animals in an in vivo model. Using an immune complexing method with the 
harvested antibody, one could isolate and enrich immunorelevant proteins from a cell lysate of the 
vaccine preparation. Further isolation of key antigens could be done using 2D electrophoresis gels 
for identification of single proteins that might be further characterized by mass spectrometry. Other 
serological evaluations such as immunoblotting could also be used to capture immunorelevant 
antigens to select for a monitoring antigen in an alternative assay using monoclonal or polyclonal 
antisera. 
i. Where antigens in the vaccine are derived from crude cell lysates or whole cell preparations, the 
use of polyclonal sera could also be used in anantigen quantification assay to measure the relative 
quantities of all immunorelevant antigens without specific characterization. The rationale of a batch 
potency test is to demonstrate consistency of antigenic properties and an immunological function 
achieved by an immunological assay. For each test, the specific criteria that the products have to 
meet for antigen quantification would need to be determined. These specifications may need to be 
determined on a per product basis because no internationally standardized reagents are available 
now or in the foreseeable future. 
Recommendations: 
• Regulators should encourage the development, validation and use of antigen quantification 
methods for batch potency testing and incorporate them into the respective guidelines and 
monographs. 
• The potential of the consistency approach and its application to the batch testing of fish vaccines 
should be evaluated. 
2.2. Waiving the use of primary cell lines for extraneous agent testing of master seeds 
The participants in the workshop believe that for the development of a fish vaccine, the use of fish to 
isolate de novo primary cells for extraneous agent testing of master seeds should not be required. The 
use of animals to create this primary cell culture(with the need to recover tissues from multiple fishes, 
multiple times in order to gain the number of cells required at a low passage number) does not make 
scientific sense. The interpretation of the relevant guidance documents [45] by medicinal authorities is 
that there needs to be testing of the master cells and seeds on a primary cell line from the species of 
origin. A primary cell line is one which is described as only one and preferably no more passages from 
the primary isolation. An argument for the use of primary cell lines is that unknown extraneous viruses 
could be better detected because primary cell lines contain a more diverse range of cell types, thus 
(potentially) increasing the chance that at least one of them may be permissive. However, even primary 
cell lines are normally of one cell type (such as epithelioid cells) and will thus not provide additional 
probability of extraneous agent detection. For fish, especially for salmonids, there are several continuous 
cell lines from the species of origin that could be used to test for extraneous agents. Any cell culture used 
for extraneous agent testing should ideally itself be shown to be free of extraneous agents, which is not 
possible when using primary cell cultures.  
Recommendation: 
• Continuous cell lines should be allowed for extraneous agent testing of master seeds. 
 
3. Potential for reduction 
The greatest potential to reduce the number of fish used for fish vaccine testing lies in the omission of 
certain tests that are of doubtful value to assure the quality, efficacy or safety of the products. These are 
discussed below. 
Apart from this, high priority should be given to reducing the numbers of fish subjected to the most severe 
procedures or to procedures inflicting clinical illness on the experimental animals. Most likely these are 
the control fish in vaccination-challenge tests, since they are unprotected and are -- by the very nature of 
the test -- expected to develop disease and, if it is not possible to implement humane endpoints, they may 
eventually die as a result. 
Recommendation: 
• Priority should be given to reducing the numbers of fish subjected to procedures that may cause 
severe outcomes. 
3.1. Re-testing for batch release in Europe only when scientifically justified 
Current European legislation requires that for veterinary medicinal products produced outside the 
European Economic Area, each batch imported to a Member State must undergo a full qualitative 
analysis, a quantitative analysis of at least all the active substances, and all other tests or controls 
necessary to ensure the quality in accordance with the requirements of the marketing authorization [44]. 
There is no scientific rationale for this when it comes to most fish vaccines imported into Europe, bearing 
in mind that target species and breeds (Atlantic salmon, rainbow trout) as well as the environmental 
conditions may be identical or essentially similar in Europe as in the country of origin. Acceptance of 
batch safety and potency data generated in the country of origin would therefore have a significant 
potential for reducing the overall numbers of fish used for fish vaccine testing. 
Recommendation: 
• Vaccines produced outside the European Economic Area should be re-tested for batch release in 
Europe only when scientifically justified. Alternatively, the manufacturers from outside Europe 
should organize that batches intended for the European market are tested only once at a certified 
testing site within the European Economic Area. 
3.2. Documentation of product safety for licensing 
It is necessary to fully assess and document the safety of a vaccine during product development. This 
requires extensive investigations on toxicological, systemic and local reactions, behavioral and 
physiological parameters, feeding, and growth. At present, double-dose safety trials are a legal 
requirement for the licensing of an inactivated fish vaccine. However, the benefits of double-dose trials vs. 
single-dose experiments to yield relevant safety data have been questioned. If samples and observations 
from single-dose experiments are shown to yield satisfactory safety documentation, relevant dual purpose 
data (safety and efficacy) could be derived from the same single-dose experiments.  
Recommendation: 
• The Ph.Eur. monograph requirements for documentation of target animal vaccine safety should 
be re-assessed for fish vaccines, giving consideration to the VICH Guideline 44, that was adopted 
during 2008 [46]. 
3.3. Safety testing for batch release 
The current European requirements stipulate a double-dose target animal batch safety test (TABST) in at 
least 10 fish (according to Ph.Eur. monographs) or at least 30 fish (according to EU guidelines). The 
reasoning behind this discrepancy remains unclear. The EU guideline on specific requirements for fish 
vaccines is currently under revision and this issue should be addressed during the revision. 
Since 2005, the Ph.Eur. general monograph on veterinary vaccines [47] allows waiving of the batch 
safety test for established vaccines in agreement with the competent authority provided that consistency 
of production has been demonstrated for at least 10 consecutive batches. The CVMP has further 
elaborated this issue in its position paper on data requirements to remove the TABST [48]. Despite this 
possibility of reduction, manufacturers are reluctant to apply it as outlined in a review document on animal 
welfare progress in Ph.Eur. monographs [49]. Reasons for this are the lack of harmonization between 
European competent authorities and with regions outside of Europe. 
Recommendations: 
• European regulators should harmonies their criteria for waiving the batch safety test. 
• The VICH should work toward harmonization of the requirements for the batch safety test for 
veterinary vaccines including fish vaccines.1 
In addition, the workshop participants suggested a different approach to batch safety testing, since the 
current safety test in at least ten animals is not determinative for the safety of adjuvanted fish vaccines 
and thus has questionable relevance for product quality. If single-dose testing would be allowed, data and 
observations derived from the vaccination of animals as part of the current in vivo potency test could be 
used for documentation of batch safety. For this purpose, specific parameters for recording safety 
relevant outcomes of single-dose immunization would need to be developed and validated. This should 
take into account the requirements outlined in the CVMP position paper “On data requirements for 
removing the target animal batch safety test for immunological medicinal products in the EU” [48]. 
In cases where a validated antigen quantification method is employed for potency testing, a separate 
single-dose safety test would have to be conducted for a certain number of consecutive batches to 
demonstrate consistency of production.  
Recommendation: 
• The approach to batch safety testing should be revised, i.e. if single-dose safety testing would be 
possible, relevant data on safety could be obtained through observations of the single-dose 
immunized fish used for batch potency testing.2 
3.4. Waiving animal use to document the seronegative status of test fish 
There is currently a requirement to document that fish used for safety testing of certain vaccines are 
seronegative. However, there are no reports describing the phenomenon of anaphylaxis in fish, nor of 
other biological effects on adverse vaccine reactions induced by the presence of antibodies to vaccine 
antigens [50]. In vaccines not based on toxoids, antibodies are considered unlikely to interfere with 
tolerance. The relevance of the requirement to prove that fish are seronegative may therefore be 
questioned. The omission of this requirement would, however have only a minor effect on reduction and  
1 Ongoing activities to remove the target animal safety test from. Ph.Eur. monographs (status 2010). 
2 Ongoing activities at VICH level on criteria for waiving the target animal safety test (status 2010). 
refinement, because testing is normally performed on entire recruitment populations (from which fish are 
drawn for multiple batch tests), and sampling is performed after sedation and stunning. 
The requirement for documenting the seronegative status of fish to be used for potency testing of Vibrio 
vaccines (or other vaccines against strictly marine pathogens) should be maintained only in cases where 
the test animal population has been exposed to seawater. Test animals of strictly freshwater origin are 
unlikely to have been exposed to these pathogens, and documentation to substantiate non-exposure to 
saltwater systems should be deemed sufficient to waive this requirement. 
Recommendations: 
• Documentation of the seronegative status of fish for safety testing should be eliminated from all 
fish vaccine monographs as the serological status is considered irrelevant to safety. 
• Documentation of the seronegative status of fish for potency testing of strictly marine pathogens 
(e.g. Vibrio spp.) should be waived when it can be demonstrated that test fish had not been 
exposed to seawater. 
3.5. Optimize vaccinated/control fish ratio 
The monograph requirements stating the minimum number of fish to be involved in efficacy 
documentation and batch potency tests should be re-assessed, aiming to minimize the number of 
unprotected control fish without compromising the statistical power of the tests. This work could build 
upon previous work addressing both statistical andbiological aspects of fish vaccination trials [50-52] and 
should also include scrutiny of pass criteria such as the estimates of relative protection (RPS). A vast 
amount of recordings could potentially be made available in anonymous form by fish vaccine 
manufacturers, creating a unique database for retrospective analysis, and allowing the use of practical 
experience as the basis for statistical assessment and optimization of test design. 
Recommendation: 
• The potential to reduce the number of control fish used in vaccination-challenge tests for efficacy 
and batch potency testing should be evaluated, since most of these unprotected fish are 
subjected to development of disease and associated distress. 
3.6. Use of genetically homogenous experimental fish strains 
In several experimental animal species, the use of genetically homogenous animals (inbred strains) is 
being employed to reduce within-group variability and thus to minimize the number of individuals 
necessary for biomedical experiments [53]. While outbred populations of fish species such as salmon, 
rainbow trout and carp are known to be immunogenetically diverse [54-56], inbred or isogenic strains of 
major aquaculture species are not currently available. Thus, the use of inbred strains is unlikely to 
contribute much to reduction in the near future. However, the workshop participants strongly encourage 
innovative academic research to assess the principal potential of genetic homogenous fish for reducing 
fish numbers in biomedical testing in the long-term perspective. 
Recommendation: 
• Research should be conducted into (i) the potential to produce inbred strains of fish, and (ii) the 
contribution that these strains could make to reducing fish use and improving scientific validity in 
biomedical research, including vaccine development and production. 
4. Potential for refinement 
Refinement has been defined as “any approach which avoids or minimizes the actual or potential pain, 
distress and other adverse effects experienced at any time during the life of the animals involved, and 
which enhances their wellbeing” [57]. The concept of refinement thus means considering the animal’s 
whole lifetime experience, not just reducing suffering during scientific procedures. 
In the case of fish used in vaccine studies, important causes of suffering or poor welfare are the effects of 
disease challenge, the side effects of vaccines (both predictable and unpredictable) and pain arising from 
scientific or husbandry procedures. For example, besides undergoing an invasive procedure, fish 
subjected to inoculation challenge will likely (even if fully or partially protected) be at least temporarily 
affected by exo- or endotoxins of the inoculum, and of bacteriaemia/viraemia, with corresponding 
physiological changes. At the other end of the scale, inoculation procedures performed under anesthesia, 
for example single-dose or even double-dose immunization for safety assessment, are believed to cause 
minimal pain or suffering in the experimental fish. 
The participants in the workshop assumed that fish may experience pain as a result of tissue damage, but 
the potential for fish to suffer due to the effects of toxins or disease has not been objectively evaluated at 
the time of writing. Therefore, it was agreed that fish are given the benefit of the doubt and that inflicting 
illness should be considered undesirable from an animal welfare viewpoint. 
4.1. Batch potency testing alternatives based on serological methods 
Serological methods (specific antibody response measurements) are a potential way of reducing the 
number of fish routinely being subjected to experimental challenge procedures. The option is already 
permitted in Ph.Eur. fish vaccine monographs. However, little progress has been made in the 
development and validation of such alternative batch potency tests. A project group has recently showed 
promising results in developing a batch potency test for oil adjuvanted furunculosis vaccines in Atlantic 
salmon by antibody ELISA (AB Romstad, pers. comm. during this workshop). A time point for blood 
sampling has been determined and the potential of the test to reveal sub-potent batches has been 
evaluated. Further work is needed to investigate whether the method can be used for the testing of 
multivalent vaccines, to evaluate intra- and interlaboratory variability, and to establish whether the 
measured antibodies in themselves are protective (by passive transfer). 
Especially for multivalent vaccines, up to six groups of fish used in parallel challenge procedures (one for 
each vaccine antigen) could be saved by using the same blood samples from one immunized group to 
confirm batch potency for all antigens. However, given the paucity of academic research on such tests 
and the economic limitations of the fish vaccine market, the costs of developing and validating such 
alternative batch test methodologies are prohibitive on a product-by-product basis. This work should be 
encouraged and sufficient funding should be mobilized to develop and validate methods for such batch 
tests and to provide the necessary reagents. This would stimulate vaccine manufacturers to adapt such 
protocols by inclusion of product-specific key reagents (e.g. antigens for coating ELISA plates, 
monoclonal antibodies, etc.). 
Obviously, the use of serological methods would also contribute to the refinement of fish vaccine trials, as 
the most invasive among the current trial procedures (experimental challenge) is no longer needed. 
Recommendation: 
• Efforts should be undertaken to develop and validate serological methods for batch potency 
testing. 
4.2. Procedures 
Procedures that may cause discomfort, pain or distress in fish vaccine studies include handling, 
identification, administration of substances in the case of challenges by injection, and killing. Guidance on 
refining some common procedures in fish can be found in the Canadian Council on Animal Care 
“Guidelines on: the care and use of fish for research, teaching and testing” [58]. 
4.2.1. Analgesia/anesthetics/sedation 
The use of analgesics, anesthetics and sedatives to reduce suffering during potentially painful or stressful 
procedures in fish should always be given full consideration. Decisions on whether these agents will be 
used should be based on judgment about the invasiveness of the procedure and the benefits of 
anesthesia or analgesia against any potential harm associated with the analgesic, anesthetic or sedative 
itself. For example, there may be trauma associated with delivery, side effects or recovery time. There is 
also evidence that some anesthetic agents can be aversive and stressful to fish [59]. A range of potential 
agents should be considered and expert advice sought in relation to their relative aversiveness, 
refinements in delivery and whether there is evidence for or against any genuine impact on scientific 
outcomes. Analgesia, anesthesia or sedation should be used whenever their benefits are considered to 
outweigh the potential harms to the fish and their use will not compromise the science (For further 
guidance see [58]). 
Examples of procedures where analgesics, anesthetics or sedatives are often used in fish vaccine testing 
are handling, identification, transport and euthanasia. The effect of analgesics on the immune response 
has not been evaluated in fish, but it may be possible in many cases to allow the agent to wash out 
before beginning scientific procedures. In addition, unrelieved pain will also have an effect on the immune 
response and thus on animal physiology. 
Recommendations: 
• Analgesics, anesthetics or sedatives should be used during any potentially painful procedure or 
stressful event, whenever the benefits are predicted to outweigh any potential harm due to 
administration trauma or side effects and the science will not be compromised. 
• More research is needed into the effects of sedatives and analgesics on the immune responses 
of fish, to alleviate concerns about interference with study objectives. 
4.2.2. Handling 
Handling is likely to be highly stressful for fish, especially if netting and holding in air is involved. It may be 
possible to avoid exposure to air, when transporting fish between tanks for example, by moving them in 
containers in water-filled containers. 
Recommendation: 
• Fish should preferably be kept in water whenever being moved 
• Exposing fish to air during handling and transport should be avoided wherever possible. 
4.2.3. Marking methods and identification of fish 
Marking individual fish for identification purposes will inevitably cause a degree of distress and discomfort, 
because it involves capture and handling as well as applying the chosen technique. Table 2 lists currently 
available techniques for identifying fish, with brief information to enable the least invasive technique to be 
chosen that is compatible with the scientific aims, any requirement to reduce numbers and the equipment 
and staff skills that are available (see also [58]). 
Note that in some instances there can be a dilemma between refinement and reduction, for example 
using Passive Integrated Transponder (PIT) tags for identification requires invasive procedures but can 
enable the number of experimental animals to be reduced. In general, the aim should be to minimize 
suffering and maximize welfare of individual animals even if more animals may be used. 
Recommendations: 
• Identification is a potentially painful and distressing procedure and therefore current knowledge 
about available techniques should be researched and the least invasive method chosen that is 
appropriate, taking into account any potential to reduce animal numbers. 
• It should be ensured that everyone who will be marking fish is appropriately competent and 
empathetic, has adequately functioning equipment and a realistic workload. 
4.2.4. Administration of substances/challenge organisms 
Substances or challenge organisms may be administered to fish using a number of routes in vaccine test 
studies such as injection, orally and by immersion. Administration by injection involves handling stress, 
the discomfort of the injection, possible pain due to tissue distension or the physico-chemical nature of 
the substance or challenge organism, and potential adverse after-effects of the substance or organism 
[60]. Less invasive administration techniques are to be preferred wherever possible; for example, 
infecting a small number of fish via waterborne exposure (ideally cohabitation) and allowing them to 
challenge other test fish is a commonly used refinement in vaccine studies. Fewer animals might be 
affected by toxic components of the challenge organism and/or temporary or permanent 
bacteriaemia/viraemia when administration is done via the water, compared to administration via 
inoculation. General guidance on refining the administration of substances was published by Morton et al. 
[61] and the CCAC [58]. 
Recommendations: 
• The least invasive or least stressful technique for administering substances or challenge 
organisms to fish that is compatible with the aims of the experiment should be used.  
• Infection by immersion, bath or cohabitation should be considered as an alternative to invasive 
administration techniques. 
• Ways to further refine the chosen method should be researched, for example by reducing needle 
gauge, improving dosing technique or selecting a less irritant carrier. 
4.2.5. Euthanasia 
New EU legislation3 states tha tmost fish should be killed either by concussion of the brain by striking of 
the cranium, or by an overdose of anesthetic using an appropriate route and anesthetic agent for the size 
and species. Electrical stunning is permitted provided that specialized equipment is used. When killed by 
anesthetic immersion, fish should be left in the solution for at least 5 min following the cessation of 
opercular  movement  and/or  vestibulo-ocular  reflex.  In both  cases,  death  should  be confirmed,  for 
3 At the time of the workshop the revision of Directive 86/609/EEC on the protection of laboratory animals 
was ongoing (http://ec.europa.eu/environment/chemicals/lab_animals/home_en.htm). The new Directive 
2010/63/EU on the protection of laboratory animals was published on 22 September 2010. 
 
example, by physical destruction of the brain or exsanguination [62]. The relative humaneness of physical 
and chemical methods, and the aversiveness of different anesthetic agents, has not been evaluated for 
fish [63]. However, some techniques used for killing fish in non-laboratory settings are clearly inhumane 
and should never be used in vaccine research, such as suffocation in air, chilling on ice or tearing gills 
(See also [58,63] and the Norwegian School of Veterinary Science website; http://oslovet.veths.no/[click 
on “fish” and “euthanasia”]). 
Table 2. Techniques for marking individual fish. 
Technique Description Welfare advantages Welfare disadvantages 
Dye or elastomer 
injection 
Small amount of dye, colored 
polymer or colored latex injected 
into the skin 





Small “chip” with unique 
identifying numbers inserted into 
the body cavity or muscle using a 
trochar or needle 
Can lead to reduction -- allows 
more sophisticated experimental 
design; potential to use 
automatic readers so no 
subsequent handling required 
Invasive technique into abdomen 
or deep into tissues 
External tags     
(Floy-tags etc.) 
Colored or numbered tag inserted 
into musculature, often just below 
dorsal fin 
Can lead to reduction -- allows 
more sophisticated experimental 
design 
Handling stress, discomfort, 
Permanent tissue penetration 
may cause ulceration and 
infection 
“Tattooing” Pigment is injected into skin cells 
using high-pressure air device 
(Panjet™) 
Long-lasting, rarely causing 
damage to dermal tissues 
Can deteriorate over time 
triggering need to be repeated 
Freeze branding Metal brand cooled to below 0˚C 
held against the skin for 3-5 s 
Long-lasting, no need for further 
handling or reapplication 
Causes tissue necrosis Not 
recommended in cold water as 
healing time increased and 
secondary infections with 
ulceration can occur 
Fin clipping Part of a fin is removed Long-lasting, no need for further 
handling or reapplication 
Nociceptors are present on fins 
so could be painful; Healing 
may result in poor discrimination; 
not recommended in cold water 
Fin removal An entire fin is removed Long-lasting, no need for further 
handling or reapplication 
Invasive marking technique; 
handling and anesthesia 
required 
Adipose fin clip Removal of adipose fin 
appendage 
Non-invasive to minimally 
techniquea 
Handling and anesthesia 
required, allows only 2 groups 
Fluorescent dyes of 
scales 
Immersion in fluorescent 
substance 
Non-invasive technique Some handling required, few 
groups only 
Otolith marking using 
rare 
earth elements 
Immersion or oral administration 
of marker substance, 
identification by biochemical 
analysis 
Non-invasive technique Fish must be euthanized before 
reading 
    
a Note: There was disagreement among workshop participants whether or not this technique could be considered non-invasive. 
 
Recommendations: 
• It should be ensured that fish are only killed by concussion, anesthetic overdose or electrical 
stunning as described above, by competent staff with an appropriate workload. 
• More research is needed into the humaneness of different techniques for killing fish of various 
sizes. 
4.3. Environment 
There are two key components in providing fish with an appropriate environment that will facilitate good 
health and welfare and minimize stress; (i) ensuring good water quality and appropriate water 
temperature and (ii) providing a stimulating environment that will encourage a range of natural behaviors. 
4.3.1. Water quality and water temperature 
Good water quality is absolutely essential for ensuring fish health and welfare. General guidance on water 
quality, including temperature and levels of oxygen, nitrogen compounds, carbon dioxide, pH and salinity, 
can be found within EU legislation [62,64] and the CCAC guidelines [58]. Precise requirements can vary 
between species and within the life cycle of individuals, so it is vital to research and provide the optimum 
water quality for each species.  
In salmonids, there is evidence that the side-effect potential of oil adjuvanted bacterin formulations may 
unfold more rapidly and vigorously at higher temperatures, i.e. at 17˚C than at 10-12˚C [65]. However, by 
elevating the water temperature, injection-site inflammatory lesions will be more severe. Research should 
be carried out to investigate the potential benefits of changing the temperature recommendations, and 
how this may lead to reduction in the number of fish used without compromising the power of these trials 
to reveal unfavorable product characteristics, or batches falling outside the acceptable safety limits. Such 
research should also address the ethical dilemma of reducing fish numbers vs. the potentially increased 
severity of reactions in each test animal used.  
4.3.2. Enrichment 
Environmental enrichment has been shown to encourage a range of natural behaviors and reduce stress 
in a range of species, which can have both animal welfare and scientific benefits. Enrichment commonly 
provided for fish used in research and testing includes variable water flow, tank shading, variety of foods, 
plants (real or artificial), species-appropriate substrate, refuges (e.g. terracotta pots, netting for fry, 
artificial nests for breeding) and rocks [66,67]. However, there may be complicating factors in the field of 
veterinary vaccine studies due to the need for stringent hygiene standards in some tests. 
Despite constraints in some studies, it should still be possible to design an environment that affords a 
degree of security and stimulation. For example, security can be provided for by adding refuges or by 
covering the tank with a solid lid, including transparent areas or portholes to allow the fish to be observed 
and monitored without lifting the lid. Fitting a lid can also help to reduce animal numbers, as fish will be 
unable to jump out of the tank. Tinted tanks, artificial water lily pads and plastic plants are other options. It 
is also important to research the natural biology and behavior of the test species when deciding on 
appropriate enrichment; for example pelagic (schooling) and riverine (territorial) fish may have different 
needs. 
For further guidance on fish husbandry see: [58,68,69 and http://oslovet.veths.no/(click on “fish” and 
“guidelines”)]. 
Recommendations: 
• It should be ensured that water quality and temperature are always within appropriate 
physiological limits. 
• Species-appropriate environmental enrichment should be provided wherever possible. 
• Fish should be housed in appropriately sized and composed groups to facilitate species-specific 
social behavior wherever protocols permit. 
• Restrictions on enrichment should be questioned and creative alternative approaches to provide 
an appropriate environment should always be sought. 
4.4. Welfare assessment 
An essential part of refinement is better recognition and assessment of the causes and effects of animal 
suffering. This helps to improve the prevention and alleviation of any pain, suffering or distress due to 
procedures as well as other effects such as anxiety. Welfare assessment is heavily dependent on 
interpreting animal behavior, but this can be especially difficult in the case of fish because their behavior 
is very different from that of mammals. In addition, it can be difficult to monitor individuals if very large 
numbers are housed together. 
An effective welfare assessment system is essential for helping to identify behaviors that are a cause for 
concern and for detecting signs of incipient suffering, thereby enabling humane endpoints to be 
implemented (see below). The ideal system will include as many objective indicators as possible (e.g. 
food consumption), consist of a small number of criteria that are easy to identify and avoid the observer 
having to make a veterinary diagnosis as part of the assessment. 
4.4.1. Signs of illness 
In response to generalized bacterial or viral infections, fish often show an enhanced respiration rate (i.e. 
more frequent opercular beats), reluctance to feed, abnormal (passive) behaviors and a reduction in 
activity as the first signs of illness [26,30]. Other examples of clinical signs that are commonly used in 
practice include skin color (especially darkened skin), red gills, decreased opercular beat rate, eye color, 
physical injury, physical abnormalities and changes in oxygen demand [67]. Physiological indicators are 
of limited use, because they are very difficult to measure without disturbing the fish, only a few have been 
documented, and many of them depend on water temperature. Behavioral signs that could indicate 
welfare problems include changes in levels of aggression, changes in swimming position, lethargy, 
separation from the rest of the school and decreased avoidance of stimuli that would normally induce 
anxiety. Very sick fish become unresponsive to external stimuli and usually float at the surface or sink to 
the bottom of the tank. This can progress to a loss of equilibrium, with fish floating “belly up” as respiration 
rate slows. At this stage mortality usually occurs (see section on humane endpoints, below). A detailed 
list of clinical signs is given in the CCAC guidelines [58]. 
4.4.2. Behavioral indications for pain and suffering 
Typical behavioral indicators of pain and suffering have been described for rainbow trout and zebrafish. In 
rainbow trout, clear signs of a noxious, potentially painful event are an increase in opercular beat rate 
from normal level of approximately 54 beats per minute to almost double (90e100 beats/min; [26]). This is 
a larger rise than a stress response (which is approximately 70 beats/min). Zebrafish also show an 
enhanced ventilation rate during nociception [30]. Trout perform anomalous behaviors such as rubbing of 
an affected area, loss of equilibrium [30] head shaking and scraping against objects [67]. There is also a 
dramatic decrease in activity in trout and zebrafish [30] but all of these changes show recovery from 3 to 
6 h after the insult [33]. 
As in other experimental animals, observation and analysis of behavior is a valuable tool in research into 
pain and welfare in fish. Inspired by Morton and Griffiths [70], Midtlyng [71] proposed a set of behavioral, 
morphological, physiological and performance parameters to evaluate vaccination side-effects relevant to 
fish welfare. Detailed guidance on the evaluation of clinical (including behavioral) signs to help assess on 
the welfare of experimental fish has recently been published by the CCAC [58]. 
4.4.3. Welfare assessment in practice 
Appendix B sets out an example of a welfare assessment system where numerical scores are assigned 
to different criteria; an alternative is the “binary” score sheet where behavioral signs are simply marked as 
present or absent. 
A “team approach” is essential when designing and using any system for recognizing and recording 
adverse effects. This requires input from researchers, animal care staff and veterinarians, all of whom 
have different specialist knowledge and experience and can bring a different perspective. The team 
should also regularly review the assessment system and adapt it as necessary to ensure that it is flexible, 
effective, agreed on by all and usable by all. It is also important to maintain knowledge of new techniques 
for observing animals, such as behavioral recognition software, other remote monitoring systems or 
techniques for measuring metabolites in the water, so that these can be trialed and brought in whenever 
feasible. Appropriate training and Continuous Professional Development is essential, which may include 
specialist courses for those using and/or caring for fish. Staff levels should also be sufficient to ensure 
that there is enough time to monitor fish effectively. 
For further guidance on welfare assessment see: [58,64,71-73] and Appendix B. 
Recommendations: 
• It should be ensured that a comprehensive welfare assessment system has been set up. 
Subjective judgments about fish welfare and adverse effects are not always reliable in isolation. 
• Welfare assessment should be tailored to the protocol and regularly reviewed, using a team 
approach. 
• Information on welfare assessment criteria and systems should be shared with other fish users, 
e.g. in publications and at meetings. 
• Information on new techniques for welfare assessment is essential; trial and use new methods 
whenever appropriate.  
• It should be ensured that there is sufficient staff with adequate time to monitor the fish effectively. 
4.5. Humane endpoints 
Humane endpoints are an essential component of humane science in all fields and there is scope to 
implement humane endpoints in all vaccine studies, including those involving fish [74,58]. The Ph.Eur. 
general monograph on veterinary vaccines permits humane endpoints [47] and the use of effective 
welfare assessment systems, as outlined above, will facilitate their implementation. Considerable 
progress has been made with respect to humane endpoints in mammals and the workshop participants 
believe that fish deserve the same consideration. 
However, there are some complicating factors in the case of vaccine testing and these need to be 
addressed. There is generally a regulatory requirement to demonstrate a degree of morbidity in vaccine 
tests, and it is necessary to be sure that animals are only killed if it is certain that they would have died as 
a result of the disease challenge within the given observation period. In other words, the clinical signs that 
determine the humane endpoint must be predictive of the required outcome of the test, e.g. mortality 
within a given period, because too many “false positives” can render a study invalid. In fish vaccine tests, 
even where endpoints have been defined, it can be difficult to identify fish that need to be euthanized in a 
tank containing large numbers. 
In practice, sick fish may not be identified until they have reached a moribund condition, which has been 
described as a severely debilitated state that precedes imminent death. The moribund state is relatively 
easy to identify, but it is considered not desirable on welfare grounds because of the suffering that the 
animal will have experienced and may still be experiencing [75]. The general aim should be to reduce the 
number of fish that become moribund in vaccine studies by increasing the implementation of effective 
assessment systems and humane endpoints. However, in studies where challenge is by cohabitation it is 
necessary to leave the moribund fish in to maximize infectivity. In this case, there is a dilemma between 
allowing one fish to suffer vs. challenging all the fish by intraperitoneal injection.  
Recommendations: 
• The use of death as an endpoint should always be questioned, especially if it is not a regulatory 
requirement.  
• Refinement of humane endpoints should be actively sought and the number of fish reaching a 
moribund state should be minimized within each study. 
• More research is needed into the identification of humane endpoints for fish in vaccine studies. 
• European Pharmacopoeia monographs for fish vaccines should specify typical clinical signs of 
the disease, include validated criteria for humane endpoints wherever available, and discourage 
death as an endpoint.  
4.6. Training 
All staff responsible for conducting procedures, monitoring fish and implementing humane endpoints or 
otherwise euthanizing fish must be both competent and empathetic. This requires not only that they are 
skilled in carrying out procedures, but also that they view fish as individuals, understand and accept that 
they can suffer, and appreciate why fish welfare is important. Training should thus include: the biology 
and behavior of the study species; recognizing and assessing both good welfare and signs of pain, 
suffering or distress; and competence in all procedures that may be carried out including euthanasia 
[76,77]. See also http://oslovet.veths.no/(click on “fish” and “education and training relating to fish            
in research” and Appendix B). In addition, the University of Prince Edward Island offers a complete 
training program for people who use fish for research, teaching and testing 
http://www.upei.ca/lifelonglearning/experimentalfish. 
Recommendation: 
• It should be ensured that the relevant staff is trained to be empathetic, as well as trained to be 
competent and knowledgeable about the species they are using and caring for. 
5. Summary of recommendations 
The participants in the workshop would like to encourage all stakeholders, manufacturers, regulators, 
researchers and animal welfare officers to follow-up the recommendations of the workshop, which can be 
summarized as follows: 
5.1. Replacement 
• The use of antigen quantification methods for batch potency testing is being encouraged 
according to the opportunities given in the respective guidelines and monographs. 
• Possibilities of applying the consistency approach to fish vaccine batch testing should be 
evaluated. 
5.2. Reduction 
• Fish vaccines produced in 3rd countries and imported to Europe should be only re-tested when 
scientifically justified and the current practice of routine re-testing should be omitted. 
• Possibility of reducing the number of control fish in vaccination-challenge tests should be 
evaluated, since most of these unprotected fish are subjected to development of disease and 
associated distress. 
• European regulators should harmonize their criteria for waiving the batch safety test.4 
• The VICH should work toward harmonization of the requirements for the batch safety test for 
veterinary vaccines including fish vaccines.5 
• Possibility of using single-dose protocols for batch safety testing should be discussed, which 
would allow combination  with the batch potency test.4 
5.3. Refinement 
• Efforts should be undertaken to develop and validate antibody induction methods for batch 
potency testing, thus making vaccination-challenge tests obsolete. Funds should be made 
available for this. 
• Death as an endpoint should be questioned whenever possible; humane endpoints should be 
applied and moribund fish be humanely killed. 
• Less invasive administration techniques are to be preferred, e.g. waterborne exposure versus 
intraperitoneal injection, and the least invasive techniques for identification should be used.  
• Welfare assessment criteria and systems for fish should be established and regularly reviewed in 
a team approach.  
• Fish should be housed in species-appropriate social groups wherever protocols permit. 
• Suitable environmental enrichment and other husbandry refinements should be sought and 
implemented. 
• Staff should be trained in welfare assessment of fish, e.g. be able to detect signs of illness (e.g. 
change in skin color e especially darkened skin -, red gills, decreased opercular beat rate, eye 
color, physical injury, physical abnormalities and changes in oxygen demand) as well as 
behavioral changes (e.g. changes in levels of aggression and swimming position, lethargy, 
separation from the rest of the school and decreased avoidance of stimuli that would normally 
induce anxiety.  
4 Ongoing activities to remove the target animal safety test from. Ph.Eur. monographs (status 2010). 
5 Ongoing activities at VICH level on criteria for waiving the target animal safety test (status 2010). 
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